Lymphoma
November 11
3 min read
Patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) receiving denileukin diftitox-cxdl demonstrated an improvement or maintenance of their overall health-related quality of life, according to findings from Study 302 presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting.